Skip to main content
. 2021 Mar 25;81(5):575–586. doi: 10.1007/s40265-021-01487-0

Table 2.

Efficacy of nintedanib in the treatment of adults with idiopathic pulmonary fibrosis [9]

Study Adjusted annual rate of decline in FVC (mL/year)a Adjusted mean change from BL in SGRQ total scoreb ≥ 1 Investigator-reported acute exacerbation (% of pts)b
INPULSIS-1
Nintedanib (n = 309) − 114.7 4.34 6.1
Placebo (n = 204) − 239.9 4.39 5.4
Difference vs placebo (95% CI) 125.3 (77.7 to 172.8)** − 0.05 (− 2.50 to 2.40)
Hazard ratio (95% CI) 1.15 (0.54 to 2.42)
INPULSIS-2
Nintedanib (n = 329) − 113.6 2.80 3.6
Placebo (n = 219) − 207.3 5.48 9.6
Difference vs placebo (95% CI) 93.7 (44.8 to 142.7)** − 2.69 (− 4.95 to − 0.43)*
Hazard ratio (95% CI) 0.38 (0.19 to 0.77)*
INPULSIS-1 and -2 (prespecified pooled analyses)
Nintedanib (n = 638) − 113.6 3.53 4.9
Placebo (n = 423) − 223.5 4.96 7.6
Difference vs placebo (95% CI) 109.9 (75.9 to 144.0)** − 1.43 (− 3.09 to 0.23)
Hazard ratio (95% CI) 0.64 (0.39 to 1.05)

BL baseline, FVC forced vital capacity, pts patients, SGRQ St. George’s Respiratory Questionnaire (range 0–100 points; higher scores indicate worse health-related quality of life)

*p < 0.05, **p < 0.001 vs placebo

aPrimary endpoint for both INPULSIS trials (analyses included all available FVC values from BL to week 52, including measurements at follow-up visits for pts who prematurely discontinued study drug; analyses allowed for missing data, assuming they were missing at random)

bAdjusted mean change from BL in SGRQ total score and time to first investigator-reported acute exacerbation were key secondary endpoints in both INPULSIS trials (assessed over 52-week treatment period and evaluated hierarchically) [fewer pts were included in SQRQ analysis]